[
  {
    "ts": "2025-05-20T12:53:00+00:00",
    "headline": "Should You Continue to Hold Charles River Stock in Your Portfolio?",
    "summary": "CRL stays on investors' radars due to the strength of partnerships and segmental prospects.",
    "url": "https://finance.yahoo.com/news/continue-hold-charles-river-stock-125300317.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "dd7d4426-19ae-3120-8f73-641439ced08d",
      "content": {
        "id": "dd7d4426-19ae-3120-8f73-641439ced08d",
        "contentType": "STORY",
        "title": "Should You Continue to Hold Charles River Stock in Your Portfolio?",
        "description": "",
        "summary": "CRL stays on investors' radars due to the strength of partnerships and segmental prospects.",
        "pubDate": "2025-05-20T12:53:00Z",
        "displayTime": "2025-05-20T12:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EzN04L.MG5n2SiOn76bXjg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1EIdoTL1xBchT1nrSboC2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/continue-hold-charles-river-stock-125300317.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/continue-hold-charles-river-stock-125300317.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-20T03:34:21+00:00",
    "headline": "Drug Development Inputs & Services Stocks Q1 Results: Benchmarking Charles River Laboratories (NYSE:CRL)",
    "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.",
    "url": "https://finance.yahoo.com/news/drug-development-inputs-services-stocks-033421308.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "f189b0be-3fdf-3f5f-9553-be331e82fa21",
      "content": {
        "id": "f189b0be-3fdf-3f5f-9553-be331e82fa21",
        "contentType": "STORY",
        "title": "Drug Development Inputs & Services Stocks Q1 Results: Benchmarking Charles River Laboratories (NYSE:CRL)",
        "description": "",
        "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.",
        "pubDate": "2025-05-20T03:34:21Z",
        "displayTime": "2025-05-20T03:34:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "CRL Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PLZRbui545u2bOcqTkunEw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YlRDliezLyxJ3r.biO59fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/drug-development-inputs-services-stocks-033421308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/drug-development-inputs-services-stocks-033421308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            },
            {
              "symbol": "UFPT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]